Use of antipsychotic medications in treating schizophrenia among different financing and delivery systems

Journal of Mental Health Policy and Economics

Volumn 6, Issue 4, 2003, Pages 163-171

  Bloom, Joan R ^a   Cheng, Jur Shan ^a   Hu, Teh Wei ^a   Kang, Soo Hyang ^a   Wallace, Neal ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PORTLAND STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; ZIPRASIDONE;

ADULT; ANTICHOLINERGIC EFFECT; ARTICLE; CAPITATION FEE; CONSUMER; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UTILIZATION; ETHNOLOGY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FINANCIAL MANAGEMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; NEUROTOXICITY; OUTCOMES RESEARCH; PRESCRIPTION; REIMBURSEMENT; SCHIZOPHRENIA; SEDATION; SIDE EFFECT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CAPITATION FEE; COLORADO; DRUG UTILIZATION REVIEW; FEE-FOR-SERVICE PLANS; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; INSURANCE COVERAGE; MALE; MIDDLE AGED; PILOT PROJECTS; SCHIZOPHRENIA;

EID: 0345765662     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Doering S, Muller E, Kopcke W, Pietzcker A, Gaebel W, Linden M, Muller P, Muller-Spahn F, Tegeler J, Schussler G. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull 1998; 24: 87-98.
2. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-429.
3. Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994; 39: S65-69.
4. Narrow WE, Rae DS, Robins LN, Regier DA. Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates. Arch Gen Psychiatry 2002; 59: 115-123.
5. McGrath J, Emmerson WB. Fortnightly review. Treatment of schizophrenia. BMJ 1999; 319: 1045-1048.
6. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999; 33: 73-85
7. Alvir JM, Lieberman JA, Safferman AZ, Schiwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-167.
8. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003; 23: 1037-1043.
9. Gianfrancesco F, White R, Wang RH, Nasrallah HA. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 2003; 23: 328-335.
10. Clark C, Burge MR. Diabetes mellitus associated with atypical anti-psychotic medications. Diabetes Technol Ther 2003; 5: 669-683.
11. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22.
12. Del Paggio D, Finley PR, Cavano JM. Clinical and economic outcomes associated with olanzapine for the treatment of psychotic symptoms in a county mental health population. Clin Ther 2002; 24: 803-817.
13. Gianfrancesco F, Durkin MB, Mahmoud R, Wang RH. Use of healthcare services by patients treated with risperidone versus conventional antipsychotic agents. Pharmacoeconomics 2002; 20: 413-427.
14. Galvin PM, Knezek LD, Rush AJ, Toprac MG, Johnson B. Clinical and economic impact of newer versus older antipsychotic medications in a community mental health center. Clin Ther 1999; 21: 1105-1116.
15. Finley PR, Sommer BR, Corbitt JL, Brunson GH, Lum BL. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998; 34: 75-81.
16. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospectivc study. Clin Ther 1993; 15: 917-926.
17. First Data Bank, Price Alert, April 1997.
18. Davis JM, Barter JT, Kane JM. Antipsychotic drugs, in comprehensive textbook of psychiatry, 5th ed, vol 2. Baltimore: Williams & Wilkins, 1989, pp 1591-1626.
19. Janicak PG, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and practice of psychopharmacotherapy. Baltimore: Williams & Wilkins, 1993, pp. 93-184.
20. Davis JM. Overview: maintenance therapy in psychiatry, I: schizophrenia. Am J psychiatry 1975; 132: 1237-1245.
21. Kane JM. Treatment programme and long-term outcome in chronic schizophrenia. Acta Psychiatr Scand (Suppl) 1990; 358: 151-157.
22. Wang PS, West JC, Tanielian T, Pincus HA. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000; 26: 451-457.
23. Domino ME, Frank RG, Rosenheck R. The diffusion of new antipsychotic medications and formulary policy. Schizophr Bull 2003; 29: 95-104.
24. Martin BC, Miller LS, Kotzan JA. Antipsychotic prescription use and costs for persons with schizophrenia in the 1990s: current trends and five year time series forecasts. Schizophr Res 2001; 47: 281-292.
25. Clark RE, Bartels SJ, Mellman TA, Peacock WJ. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002; 28: 75-84.
26. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 2002; 28: 31-42.
27. Johnson RD, McFarland BH. Antipsychotic drug exposure in a health maintenance organization. Med Care 1993; 31: 432-444.
28. Carroll NV. How effectively do managed care organizations influence prescribing and dispensing decisions? Am J Manag Care 2002; 8: 1041-1054.
29. Luo RD, Belleti DA, Tran D, Arcona S, Salen PN. National prescribing patterns in the management of extrapyramidal symptoms among patients with schizophrenia. Int J Psychiatry Med 2002; 32: 261-269.
30. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993; 26: 121-124.
31. Muller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. Clin Neuropharmacol 1992; 15 Suppl 1: 90A-91A.
32. Shopsin B, Klein H, Aaronsom M, Collora M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry 1979; 36: 657-664.
33. Bloom JR, Hu TW, Wallace N, Cuffel B, Hausman J, Scheffler R. Mental health costs and outcomes under alternative capitation systems in Colorado: early results. J Ment Health Policy Econ 1998; 1: 3-13.
34. Wallace N, Bloom, JR, Hu, TW. Patterns of Antipsychotic Medication Utilization under Medicaid Capitation Financing. (under preparation).
35. Hudson TJ, Sullivan G, Feng W, Owen RR, Thrush CR. Economic evaluations of novel antipsychotic medications: a literature review. Schizophr Res 2003; 60: 199-218.
36. Mark TL, Dirani R, Slade E, Russo PA. Access to new medications to treat schizophrenia. J Behav Health Serv 2002; 29: 15-29.
37. Kuno E, Rothbard AB. Racial disparities in antipsychotic prescription patterns for patients with schizophrenia. Am J Psychiatry 2002; 159: 567-572.
38. Jin H, Folsom DP, Lindamer L, Bailey A, Hawthorne W, Garcia P, Jeste DV. Patterns of public mental health service use by age in patients with schizophrenia. Am J Geriatr Psychiatry 2003; 11: 525-533.
39. Trierweiler SJ, Neighbors HW, Munday C, Thompson EE, Binion VJ, Gomez JP. Clinician attributions associated with the diagnosis of schizophrenia in African American and non-African American patients. J Consult Clin Psychol 2000; 68: 171-175.